| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11844858 | FAMYGEN LIFE SCI | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
Jan, 2034
(9 years from now) | |
| US9795560 | FAMYGEN LIFE SCI | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
Jan, 2034
(9 years from now) | |
| US11090261 | FAMYGEN LIFE SCI | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
Jan, 2034
(9 years from now) | |
| US10278918 | FAMYGEN LIFE SCI | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
Jan, 2034
(9 years from now) | |
| US10772829 | FAMYGEN LIFE SCI | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
Jan, 2034
(9 years from now) | |
| US11400077 | FAMYGEN LIFE SCI | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders |
Oct, 2039
(15 years from now) | |
Ryzumvi is owned by Famygen Life Sci.
Ryzumvi contains Phentolamine Mesylate.
Ryzumvi has a total of 6 drug patents out of which 0 drug patents have expired.
Ryzumvi was authorised for market use on 25 September, 2023.
Ryzumvi is available in solution;ophthalmic dosage forms.
Ryzumvi can be used as treatment of pharmacologically-induced mydriasis.
The generics of Ryzumvi are possible to be released after 25 October, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 25, 2026 |
Drugs and Companies using PHENTOLAMINE MESYLATE ingredient
Market Authorisation Date: 25 September, 2023
Treatment: Treatment of pharmacologically-induced mydriasis
Dosage: SOLUTION;OPHTHALMIC
More Information on Dosage
RYZUMVI family patents
